SuperworthSS Innovations International SSII
- Market cap
- $450.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 8.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $52.4M
- +90% on a year ago
- Net margin
- −23.7%
- Free cash flow yield
- −4.0%
SS Innovations International trades at 8.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $52.4M over the last twelve months, up 90% on a year earlier with a −24% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.2M+313% | $1.4M+57% | $3.6M+883% | $4.5M+138% | $4.4M+101% | $8.1M+469% | $5.1M+41% | $10M+122% | $12.8M+193% | $14.5M+79% | $11.1M+117% | $13.9M+39% | |
| Cost of revenue | $1.9M+554% | $1.8M+70% | $2.9M+896% | $3.1M+173% | $2.1M+10% | $4.1M+125% | $4M+39% | $4.1M+33% | $6.7M+222% | $8.2M+97% | $5.8M+43% | $6.8M+67% |
| Gross profit | $298.8K+24% | −$419K+133% | $728.2K+834% | $1.4M+87% | $2.3M+675% | $4M | $1.1M+49% | $5.9M+311% | $6.2M+166% | $6.4M+61% | $5.3M+390% | $7.1M+20% |
| R&D | $291.9K+87% | $278.2K+796% | $528K+118% | $759K+208% | $442.8K+52% | $761.9K+174% | $1M+91% | $498.6K−34% | $786.3K+78% | $1.4M+83% | $995.4K−2% | $2.4M+381% |
| SG&A | $1.8M+271% | $1.7M+90% | $2.8M+225% | $2.2M−60% | $2.5M+40% | $2.6M+49% | $3.4M+20% | $3.4M+53% | $4.8M+92% | $3.4M+32% | $4.5M+32% | $4.5M+30% |
| −$1.9M+335% | −$12.2M+169% | −$9.8M+818% | −$4.1M−21% | −$3.2M+73% | −$1.8M−85% | −$5.9M−40% | $97K | −$1.8M−43% | −$735K−60% | −$3.6M−39% | −$2.3M | |
| Interest expense | $134.7K+115% | $138.1K−12% | $190.1K−26% | $242.6K−34% | $247.6K+84% | $293K+112% | $379.9K+100% | $216.8K−11% | $176.6K−29% | $335.3K+15% | $284.1K−25% | $344.8K+59% |
| Pre-tax income | −$1.9M+290% | −$12.1M+936% | −$9.8M+650% | −$4.1M−25% | −$3.2M+71% | −$1.9M−84% | −$5.7M−42% | $97K | −$1.9M−42% | −$705.7K−63% | −$3.4M−40% | −$2.2M |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $353.7K | $1.8M | $1.8M | $151.4K | $505.3K+43% | |
| Net income | −$1.9M+290% | −$12.1M+936% | −$9.8M+650% | −$4.1M−25% | −$3.2M+71% | −$1.9M−84% | −$5.7M−42% | −$256.7K−94% | −$3.7M+15% | −$2.5M+29% | −$3.6M−37% | −$2.7M+937% |
| −$0.01 | −$0.08−60% | −$0.06+500% | −$0.02−50% | −$0.02+100% | −$0.01−88% | −$0.03−50% | $0.00 | −$0.02+0% | −$0.01+0% | −$0.02−33% | −$0.01 | |
| 147.8M+15% | 159.6M+237% | 181.6M+42% | 181.8M+27% | 181.9M+23% | 171.1M+7% | 188.6M+4% | 202.8M+12% | 202.9M+12% | 193.8M+13% | 205.3M+9% | 209.4M+3% |
R&D: Q1 FY16: 6 months less the 3 months printed beside them.
SG&A: Q1 FY16: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
Net income: Q1 FY16 and Q1 FY17: 6 months less the 3 months printed beside them.
EPS, diluted: 22 periods, Q1 FY16 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY16: share-days: the 6-month average less the second quarter's. 9 periods, Q4 FY16 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest SS Innovations International's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SSIISS Innovations International | $450.9M | n/m | n/a | 8.6× | +90% | −23.7% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| Peer median | $552.7M | 22.3× | 24.1× | 2.0× | +4% | 7.8% |
More on SS Innovations International
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .